Meeting
2016 ASCO Annual Meeting
Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC).
Authors
Andreas Dietz
University of Leipzig, Leipzig, Germany
Andreas Dietz , Gunnar Wichmann , Michael Flentje , Rudolf Hagen , Oliver Koelbl , Frank Schreiber , Volker Schilling , Georg Maschmeyer , Ursula Schroeder , Christian Sittel , Thomas Lenarz , Jens Peter Klussmann , Orlando Guntinas-Lichius , Claudia Rudack , Thomas Foerg , Martin Westhofen , Hans Juergen Welkoborsky , Dirk Esser , Swantje Held , Ulrich Keilholz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT00508664
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6025)
DOI
10.1200/JCO.2016.34.15_suppl.6025
Abstract #
6025
Poster Bd #
347
Abstract Disclosures
Similar Posters
First Author: Andreas Dietz
Poster
2019 ASCO Annual Meeting
Induction chemotherapy with docetaxel, cisplatin and cetuximab versus docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced or inoperable squamous cell carcinoma of the head and neck: Promising results of a randomized phase II AGMT-trial.
First Author: Felix Keil
Poster
2016 ASCO Annual Meeting
TPF plus cetuximab (E) induction chemotherapy (ICT) followed by biochemoradiation (BCRT) with weekly E plus weekly cisplatin (P) or carboplatin (C) in stage III/IV squamous cell carcinoma of the head and neck (HNSCC): A randomized phase II EORTC trial.
First Author: Pol M. Specenier
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli